RXRX - NASDAQ
Recursion Pharmaceuticals, Inc.
$3.47
-8.4%Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
At a Glance
Live SnapshotRecursion Pharmaceuticals, Inc. Management Team
Mr. Ben R. Taylor
Chief Financial Officer & President of Recursion UK
Compensation
$669,109
Mr. Nathan Hatfield J.D., M.B.A.
Chief Legal Officer & General Counsel
Dr. David J. Mauro M.D., Ph.D.
Chief Medical Officer
Compensation
$793,399
Ms. Kristen Rushton M.B.A.
Chief Operating Officer
Ms. Erica Fox
Chief People and Impact Officer
Dr. Najat Khan Ph.D.
Chief R&D Officer, Chief Commercial Officer and Director
Compensation
$955,009
Dr. David Hallett Ph.D.
Chief Scientific Officer
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Compensation
$860,270
Kevin Leggat
Vice President of Finance & Accounting
Recursion Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $11.93M worth of RXRX shares, with no buying activity reported.
3 Months
0
0.00
296.3K
976.63K
-977K
-$977K
3-6 Months
0
0.00
969.2K
3.98M
-4.0M
-$3.98M
6-9 Months
0
0.00
740.0K
3.64M
-3.6M
-$3.64M
9-12 Months
0
0.00
636.9K
3.33M
-3.3M
-$3.33M
Top Buyers
No buying activity
Top Sellers
Gibson Christopher
Director
$7.29M
Borgeson Blake
Director
$3.63M
Khan Najat
Director, Officer: Ceo And President
$845K
Taylor Ben R
Officer: Chief Financial Officer
$158K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $11.93M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
RXRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | April 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 03, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 14, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.